Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
Colorectal cancer is not the only gastrointestinal cancer that doctors are diagnosing in patients below the age of 50.
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
2
Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL
3
Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5